STOCK TITAN

[6-K] GSK plc American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of September 2025
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
GSK plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Victoria Whyte
b)
Position/status
SVP & Company Secretary
 
c)
Initial notification/ amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Award of Ordinary Shares under the Company's 2025 Share Value Plan
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£14.4250
10,050
 
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume Price
 
 
e)
Date of the transaction
 
2025-09-02
f)
Place of the transaction
 
N/A
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: September 04, 2025
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc
GSK PLC

NYSE:GSK

GSK Rankings

GSK Latest News

GSK Latest SEC Filings

GSK Stock Data

79.26B
2.03B
0.06%
19.07%
0.62%
Drug Manufacturers - General
Healthcare
Link
United Kingdom
London